A carregar...
Filgrastim associations with CAR T‐cell therapy
Little is known about the benefits and risks of myeloid growth factor administration after chimeric antigen receptor (CAR) T‐cell therapy for diffuse large B‐cell lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who received CAR T‐cell therapy with ax...
Na minha lista:
| Publicado no: | Int J Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894177/ https://ncbi.nlm.nih.gov/pubmed/33091961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33356 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|